Recursion Pharmaceuticals
Rating
Key Statistics
Market Data
Valuation (TTM)
Valuation (NTM)
Cash Flow
Margins
Growth (CAGR)
Returns
Financial Health
Dividends
Profile
Recursion Pharmaceuticals, Inc. operates as a biotechnology firm currently in its clinical development phase. The company's mission is to revolutionize drug discovery by decoding biological processes,...
Latest News
5 days ago · finbold.com
2 healthcare stocks to turn $10 into $100 by next yearHealthcare stocks have emerged as an area of relative strength in 2026, outperforming technology shares as investors seek opportunities beyond the artificial intelligence (AI) boom.
5 days ago · globenewswire.com
Recursion to Participate in Upcoming Investor ConferencesSalt Lake City, UT, Nov. 11, 2026 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX), a leading clinical-stage company pioneering AI-enabled drug discovery and development, today announced its participation in the following upcoming investor conferences: Jefferies Global Healthcare Conference London — Wednesday, November 18, 2026 Evercore 9th Annual Healthcare Conference — Monday, November 30, 2026 Citi's 2026 Global Healthcare Conference — Tuesday, December 1, 2026 Webcasts may be found in the events section of the Recursion Investor Relations website at ir.recursion.com . About Recursion Recursion (Nasdaq: RXRX) is a leading clinical-stage company pioneering AI-enabled drug discovery and development decoding biology to radically improve lives.
13 days ago · zacks.com
RXRX Q3 Earnings Call Highlights Clinical Progress and Cash RunwayRecursion highlights promising clinical data for REC-4881 and REC-1245, beats Q3 earnings estimates and extends its cash runway into 2029 through disciplined spending.
13 days ago · seekingalpha.com
Recursion Pharmaceuticals, Inc. (RXRX) Q3 2026 Earnings Call TranscriptRecursion Pharmaceuticals, Inc. ( RXRX ) Q3 2026 Earnings Call November 3, 2026 8:00 AM EST Company Participants Najat Khan - CEO, President & Director Vicki Goodman - Chief Medical Officer Ben Taylor - CFO & President of Recursion UK Conference Call Participants Evelien Dekker Bryson Katona Jesse Laster Lindsay Huff Laura Laster Presentation Najat Khan CEO, President & Director Good morning, everyone, and thank you for joining Recursion's Third Quarter Earnings Call. We're hosting earnings live from the CGA-IGC Annual Meeting in Denver.
14 days ago · marketbeat.com
What Recursion Pharmaceuticals (RXRX) Said on Its Q3 Earnings CallRecursion Pharmaceuticals NASDAQ: RXRX reported updated clinical data for its investigational treatment for familial adenomatous polyposis, or FAP, along with early activity in its solid-tumor program REC-1245, partnership progress and an extension of its expected cash runway into 2029.
14 days ago · zacks.com
Recursion Pharmaceuticals (RXRX) Reports Q3 Loss, Tops Revenue EstimatesRecursion Pharmaceuticals (RXRX) came out with a quarterly loss of $0.22 per share versus the Zacks Consensus Estimate of a loss of $0.24. This compares to a loss of $0.36 per share a year ago.
14 days ago · globenewswire.com
Recursion Appoints Fred Hassan as Chair of the BoardSalt Lake City, UT, Nov. 02, 2026 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX), a leading clinical-stage company pioneering AI-enabled drug discovery and development, today announced that its Board of Directors has appointed Fred Hassan as Chair, effective October 31, 2026 Mr. Hassan arrives with a strong track record of more than four decades in the pharmaceutical industry. He has grown global businesses and led teams that brought multiple medicines through development, regulatory approval and commercial launch. As an example, the severely challenged Schering-Plough returned to sales growth, strong cash flow, and expanded the number of new molecular entities in Phase 3 development from three to eight.
17 days ago · zacks.com
Recursion Pharmaceuticals (RXRX) Declines More Than Market: Some Information for InvestorsRecursion Pharmaceuticals (RXRX) closed the most recent trading day at $4.03, moving 4.95% from the previous trading session.
19 days ago · zacks.com
Recursion Pharmaceuticals to Report Q3 Earnings: What's in the Cards?RXRX heads into Q3 earnings with key collaboration milestones, advancing clinical programs and upcoming pipeline updates that could shape its outlook.
20 days ago · zacks.com
Recursion Pharmaceuticals (RXRX) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 ReleaseRecursion Pharmaceuticals (RXRX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Earnings
Analyst Summary
Add to Watchlist
Select watchlists to add or remove RXRX